ALDX FY 2012 Earnings — Aldeyra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALDXAldeyra Therapeutics, Inc.

$297M

FY 2012 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$1M

Net Income

-$23M

EPS (Diluted)

$-19.22

Cash Flow

Operating Cash Flow

-$778,046

Free Cash Flow

-$778,046

Stock-Based Comp.

$84,401

Balance Sheet

Total Assets

$2M

Total Liabilities

$27M

Stockholders' Equity

-$25M

Cash & Equivalents

$1M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$1M	-$2M	+47.2%
Net Income	-$23M	-$2M	-870.4%